Paraneoplastic leukemoid reaction as a marker of tumor progression in non-small cell lung cancer

Caroline E. McCoach, Jessica G. Rogers, Denis M Dwyre, Brian Jonas

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background: Paraneoplastic leukemoid reaction (PLR) is a well-described entity in which the white blood cell count expands to greater than 50,000/mm3 in association with malignancy. It is thought to occur in approximately 10-15% of cancers. Notably, PLR is known to be predictive of a poor prognosis. Recent work has demonstrated that there may be a relationship between PLR activated by intratumoral production of granulocyte colony-simulating factor (G-CSF), the RAS/RAF/MEK pathway and tumorogenesis. Specifically, activation of the RAS/RAF/MEK pathway is thought to regulate G-CSF production, which in turn, mediates expansion and mobilization of cells that produce factors that promote tumor metastasis. Methods/results: In this report we demonstrate the PLR response to treatment in a patient with non-small cell lung cancer. Additionally, we demonstrate elevated G-CSF in the patient[U+05F3]s serum 507. pg/ml (0-39.1. pg/ml) and positive staining by immunohistochemistry of G-CSF in the patient[U+05F3]s tumor tissue. Finally, we describe a possible pathway by which this promotes tumor spread. Conclusion: Though G-CSF has been traditionally viewed as a prognostic marker, here we provide evidence that it may be a valuable marker to investigate for treatment response at a cellular level.

Original languageEnglish (US)
Pages (from-to)15-18
Number of pages4
JournalCancer Treatment Communications
Volume4
DOIs
StatePublished - 2015

Keywords

  • G-CSF
  • Lung cancer
  • Paraneoplastic leukemoid reaction
  • RAS/RAF/MEK
  • Tumorigenesis

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Paraneoplastic leukemoid reaction as a marker of tumor progression in non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this